Brief: Natco Pharma Announces Conclusion Of US FDA Inspection
19/06/2025 14:11
June 19 (Reuters) - Natco Pharma Ltd NATP.NS: NATCO PHARMA LTD - ANNOUNCES CONCLUSION OF US FDA INSPECTION NATCO PHARMA LTD - COMPANY RECEIVED 7 OBSERVATIONS IN FORM-483 NATCO PHARMA LTD - FDA INSPECTION CONDUCTED FROM JUNE 9TH TO JUNE 19TH, 2025 AT KOTHUR Source text: ID:nBSE5QkRr3 Further company coverage: NATP.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees